What a biomarker result can and cannot tell you
A biomarker is a measurable feature of the tumour or the patient that can inform treatment selection. In immunotherapy, certain markers may help a clinician judge whether a specific agent is worth considering for a given cancer type. That is a clinical judgement, not a lookup. Immunotherapy helps the immune system act against cancer, and whether it is appropriate depends on the cancer and individual assessment.
The practical consequence for an overseas patient is that a biomarker report alone cannot answer the question 'can I receive immunotherapy in China?' It can support a specialist discussion, but suitability, drug availability and monitoring plans remain decisions for the treating hospital and licensed clinicians. A positive or negative marker does not by itself establish that a treatment will work, that it will be safe for you, or that a particular hospital can provide it.
It also matters which test was done, on what sample, and when. A result from an older biopsy, a small sample, or a different laboratory may not be directly comparable with what a receiving team needs. Rather than assuming your file is complete, ask the hospital what it requires for the specific treatment being considered.
Why the tumour type and treatment history change the question
Biomarkers are interpreted within a disease context. The same marker can carry different weight in different cancers, and prior treatments can change which options remain reasonable. If you have already received one line of therapy, the next decision depends on how the disease responded, what toxicity occurred, and how much time has passed.
This is why a generic list of 'immunotherapy biomarkers' is not enough for a China enquiry. The specialist needs to know the exact diagnosis, stage, prior systemic treatments, dates, responses and any immune-related side effects. A history of an autoimmune condition or prior immune toxicity is directly relevant to whether immunotherapy is appropriate and how it would be monitored.
When you write to a hospital or coordination service, lead with the diagnosis and the specific question. For example: 'I have [cancer type], previously treated with [treatment], and I want to know whether biomarker testing is needed before considering immunotherapy.' That framing lets the team identify missing information instead of guessing.
Records to prepare before asking about immunotherapy
You do not need to send a complete archive at first contact. A brief summary is enough to start. After that, the hospital will usually ask for the documents it needs to assess the case. Preparing these in advance reduces back-and-forth.
The core items are the pathology report with the exact diagnosis and any biomarker results, imaging reports and the actual images if available, operative or biopsy notes, and a chronological summary of prior treatments with dates and responses. If you have had genomic testing, include the full report rather than a one-line summary, because the panel, the assay and the variants detected all matter.
Ask the receiving team which language it needs and whether it requires certified translation. Do not assume that a report from your home laboratory will be accepted without review. A pathology re-review or additional testing may be requested, and that is a clinical decision for the hospital, not something to arrange on your own initiative.
Questions that clarify whether the treatment fits your case
The most useful questions are specific and answerable. They also reveal whether the hospital has enough information to give a meaningful opinion.
Ask: which biomarker result is relevant to the immunotherapy being considered, and is my existing test adequate or is further testing needed? Has my pathology been reviewed locally, and does the review change the interpretation? Given my prior treatments and any immune-related history, what are the main uncertainties about suitability? What alternatives would be considered if immunotherapy is not appropriate?
On monitoring, ask how response and side effects would be followed, what would trigger an urgent review, and how the plan would be handed back to your home clinician. Immunotherapy can cause immune-related adverse effects that may need prompt assessment, so the monitoring plan is part of the treatment decision, not an afterthought.
Finally, ask directly whether the specific treatment is appropriate and available for your diagnosis at that hospital. Availability is a hospital-level fact that changes over time; it should be confirmed in writing for your case rather than assumed from a general statement.
How monitoring would continue after you return home
For many patients, the practical question is not only whether treatment can start in China but how follow-up would work afterwards. This needs to be discussed before travel, because it affects the treatment plan itself. Immunotherapy is not a single course with a fixed endpoint. Some regimens continue for a defined number of cycles; others are given until a specific event occurs, such as disease progression or unacceptable toxicity. The monitoring schedule follows from that design, and it determines what can realistically be done at home and what needs to happen at the treating hospital.
Ask the treating team what monitoring is required, how often, and which tests can be done locally. Request a written summary of the regimen, the expected duration, the side effects to watch for, and the criteria for contacting a clinician urgently. Ask who at home would receive that summary and whether the hospital is willing to communicate with your local oncologist.
Immune-related adverse effects can appear during treatment or after it has stopped, and they can affect organs such as the skin, gut, thyroid, liver or lungs. That is why the monitoring plan needs to name the specific tests, the interval between them, and the symptoms that should trigger an urgent call rather than a wait-and-see approach. A plan that says only 'follow up locally' leaves the home clinician without the information needed to act.
The handover itself is a concrete task. Ask whether the hospital will provide a written treatment summary in English, whether it will include the exact regimen and cumulative doses given, and whether it will respond to questions from your home oncologist after you leave. If the answer is that communication would go through you as the patient, that changes what you need to arrange before departure, so it is worth clarifying early rather than assuming.
Do not stop or interrupt current treatment to pursue an overseas enquiry. If your disease is progressing or you have new or worsening symptoms, local urgent assessment takes priority. An overseas review can proceed in parallel, but it should not delay necessary care.
A practical next step is to ask the hospital, in writing, for its monitoring and handover plan for your case, including who at home would receive the summary and how questions would be answered after you return.
What to send first and what happens next
Start with a short summary: diagnosis, stage, prior treatments with dates, biomarker results if available, current symptoms, and the specific question you want answered. You can send this by the enquiry form, email or WhatsApp. Do not send passport numbers, card details or a complete medical archive at this stage.
The team checks the available diagnosis, records and your main question, identifies missing information and suggests the relevant next step. This initial review is free and is not a diagnosis or a promise of acceptance. If a records-based specialist opinion is useful, that is a separate optional step, and it is not a prerequisite for every appointment or operation.
A useful next step is to write one paragraph stating your diagnosis, prior treatment and the exact biomarker question you want the hospital to address, then send it for initial review. The hospital decides suitability, and any treatment, monitoring or access question should be confirmed with the treating clinicians for your individual case.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.